Vectura Share Discussion Threads

[diesel] 18/1/2017 10:56

Well there's a seller, not significant numbers but the market might get spooked by a big holder reducing. We will know if the uptrend of the last few months gets broken...

[pooroldboy55] 18/1/2017 08:42

Agree , alord53

[a1ord53] 18/1/2017 08:13

AO , if were seller/s with more than 3% , we should have rns already.
We dont have rns yet, so it means that seller/s have less than 3% or we have short seller/s.
sp is under pressure despite buy recommendations almost of all analysts.

[a0148009] 17/1/2017 22:53

If there is a seller and they have over 3% there should be an RNS in the near future,if there is more than one seller over 3% it could take some time.
AO

[dontay] 17/1/2017 17:58

There is definitely a very large overhang holding the share price back IMO... it has been going on for a while... so I think it more likely to be a fund manager, possibly slowly readjusting a funds weighting levels after the merger? The share price is trying to rise but is constantly being held back... it's simply not being allowed to reflect VEC's recent interim results, recent reasonably good pipeline news, the two industry reports, (Gold and Crystal) expected excellent full yr results, or future prospects. Trump isn't helping but I think his mouth is nothing to be overly concerned about. Could well be a few more millions to be sold yet... but once cleared I think it's possible we will a re-rating.

[pooroldboy55] 17/1/2017 11:39

Can it still be SKP holders selling ? but someone is.

[jopper74] 16/1/2017 17:06

Looks like they are trying to tempt sellers out......maybe got an order to fill?

[pooroldboy55] 16/1/2017 16:16

Back to normal up am down pm

[soseiman] 15/1/2017 06:15

Hi.
About Ultibro in China, the review status has been updated on January 6th.
Technical review is completed, now it is the phase of approval review.
Based on the review rules, I estimate that the approval review will be completed within this fiscal year.
Of course I do not know whether there are announcements from Novartis.

In the not too distant future, I hope that there will be good news about Ultibro in China.

[dontay] 12/1/2017 13:20

Carpadium... agreed, currently it does indeed seem to be shaping up for there being a long lull in pipeline news for that period. An announcement at a suitable time after the Advair news release in the spring.... of some serious future plan to pay a reasonable dividend... might also help 'fill the gap' to 2020.

[richtea1701] 12/1/2017 11:23

I thought the presentation was very confident

[alexchry] 12/1/2017 07:55

I listened to the webcast last night, all very positive and bullish but nothing new. WL said a number of times that the share price was only valued on current products and took no account of the very strong set of seven late stage developments. He also mentioned M&A activity a few times but said that they were in no rush, they would spend their money wisely. He covered newsflow for 2017 but no mention at all of the COPD trial. Unfortunately, the Q&A session was not covered on my newscast, that is often the most revealing bit.

[carpadium] 12/1/2017 07:43

Last night's US J P Morgan presentation, also available as webcast ...

[alexchry] 11/1/2017 18:25

Not a good backdrop to Ward-Lilley's presentation later!

[dp1umb] 11/1/2017 18:00

Also btg as he opened his big mouth, what a clown

[carpadium] 11/1/2017 17:43

We were going quite nicely until Trump opened his mouth ... AZN, GSK, HIK all fell sharply towards the end of trading.

[rivaldo] 11/1/2017 10:02

Reacting well now.

Numis have reiterated their Buy and 252p price target. They say:

"VECTURA (BUY, 252p) Full year pre-close update.

Vectura confirmed that it expects revenues for 2016 (shortened 9 months as Y/E moves to Dec) to be in line with expectations (NSe £110m, pro-forma growth of c.8% and c.19% in recurring revenues), with positive momentum from the seven inhalers with Vectura technology inside being rolled out globally. The statement notes record Flutiform volumes in the supply chain with good progress being made to expand capacity, and that Ultibro continues to benefit from the landmark clinical trials reported in 2016. Pacira Q4s reported c.6% growth of Exparel to $71.4m in line with Pacira consensus and our forecasts.

The statement summarises a busy period for business development / regulatory action (prior releases) with two deals announced with Mundipharma exercising its option on the asthma triple inhaler VR2076 and Sunovion licensing US rights to the Utibron and Seebri COPD inhalers from Novartis, while Bayer confirmed the first global regulatory approval of the FOX handheld nebuliser device (VR876).

We make one change to our model to update for the recent deal with Mundipharma in late December, which triggered an upfront of €1.5m which raises our forecast FY2016 EBITDA to £27.8m from £26.5m (+5%).

With Vectura increasing its profile as the partner of choice in targeting the airways in 2016, we expect to see further deals in 2017. VR315 (generic Advair) is highlighted as an important catalyst in the year, with the FDA approval decision on 10 May coming into near-term view. Next anticipated news is an update on Ultibro sales in Novartis Q4 results on 25 January."

[soundbuy] 11/1/2017 09:21

Currency gains offset by inflationary pressures?

None too sure but expect to see this being rolled out from companies going fwd.

All steady....

[diesel] 11/1/2017 08:17

Yup Alex, pretty steady, nothing to set the market alight. Always amuses me that ' in line with expectations' statement, they weren't expectations currency gains so they must have lost out somewhere else. Still worth holding for a while longer...

[alexchry] 11/1/2017 07:27

Just read the pre-close update. My summary would be satisfactory progress made, bit disappointing really because as a Skyepharma shareholder I'd got used to reading 'results ahead of expectations'. Nothing new in the update but it's only a few weeks since the interim results so wouldn't expect much. It doesn't look as though we'll be getting the milestone for Exparel any time soon. The biggest disappointment for me was no mention of the major COPD trial for China/Asia, the results of which were due by the end of 2016. This makes me think that it will be bad news. I hope not but as the previous COPD trial failed, expectations must have been low, I do hope bad news is already in the share price The great white hope for this year is the advair generic but we've another four months to wait for news on that. Ward-Lilley is presenting in the US tonight, that might give a boost to the SP, wonder if he'll come back with an acquisition in his pocket!

[gbcol] 11/1/2017 07:21

Pre-close update out.

[rivaldo] 10/1/2017 10:41

Going well again.

[boadicea] 09/1/2017 15:14

I was basing my uptrend on the succession of higher lows which has followed the bottom found in early September last. There is also a trend of higher highs although we haven't had one since ~151p around 20th Nov - so another one is overdue!
Taken together these define a wideish channel currently extending from 135 to 155p.

So I have 155p as an early target for resistance (or breakout) - just waiting for a good news release to test it.